Novo Nordisk says CagriSema outperforms semaglutide in late-stage trial of type-2 diabetes patients

Core Insights - Novo Nordisk's experimental weight-loss drug CagriSema demonstrated superior efficacy in reducing blood sugar levels and body weight compared to semaglutide alone in a late-stage trial involving patients with type 2 diabetes [1] Group 1 - CagriSema is a next-generation weight-loss drug developed by Novo Nordisk [1] - The late-stage trial focused on patients diagnosed with type 2 diabetes [1] - Results indicated that CagriSema outperformed semaglutide in both blood sugar reduction and weight loss [1]